Each Representing One-Tenth of One Ordinary Share (nominal value DKK 1 per share) UNDERWRITING AGREEMENTUnderwriting Agreement • July 9th, 2019 • Genmab a/S • Pharmaceutical preparations • New York
AMENDED AND RESTATED DEPOSIT AGREEMENT by and among GENMAB A/S AND DEUTSCHE BANK TRUST COMPANY AMERICAS as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ISSUED HEREUNDER Dated...Deposit Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT, dated as of , 2019, by and among (i) Genmab A/S, a company incorporated under the laws of the Kingdom of Denmark, and its successors (the “Company”), (ii) Deutsche Bank Trust Company Americas, an indirect wholly owned subsidiary of Deutsche Bank A.G., acting in its capacity as depositary, and any successor depositary hereunder (the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares evidenced by American Depositary Receipts issued hereunder (all such capitalized terms as hereinafter defined).
AMENDMENT NO. 5 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENTDevelopment and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This Amendment No. 5 (this “Amendment No. 5”) to the Current Agreement (as defined below) is made as of January 22, 2018 (the “Amendment Effective Date”)
Execution CopyLicense Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
JOINT COMMERCIALIZATION AGREEMENT by and between GENMAB A/S and SEAGEN INC. Dated as of October 19, 2020Joint Commercialization Agreement • March 29th, 2021 • Genmab a/S • Pharmaceutical preparations • New York
THIS JOINT COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of October 19, 2020 (the “Effective Date”), by and between GENMAB A/S, a Danish corporation (“Genmab”), and SEAGEN INC. (f/k/a SEATTLE GENETICS, INC.), a Delaware corporation (“SGI”). Genmab and SGI are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
AMENDMENT NO. 1 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006 (the “Agreement”)The Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 1”) is made and entered into as of the day of , 2008 (the “Amendment Effective Date”), between
AMENDMENT NO. 3 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006, AS AMENDED (the “Agreement”)The Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 3”) is made and entered into as of the 1st day of July, 2010 (the “Amendment Effective Date”), between
AMENDMENT NO. 2 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006 (the “Agreement”)The Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 2”) is made and entered into as of the 18th day of December, 2008 (the “Amendment Effective Date”), between
ContractGenmab a/S • May 28th, 2019 • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
Execution CopyLicense Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations • New York
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
Execution CopyLicense Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
AMENDED AND RESTATED EVALUATION AND COMMERCIALIZATION AGREEMENTEvaluation and Commercialization Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
THIS AMENDED AND RESTATED EVALUATION AND COMMERCIALIZATION AGREEMENT (the “Agreement”), entered into as of July 12, 2012 (the “Execution Date”) but effective as of February 25, 1999 (the “Effective Date”), is entered into by and between Bristol-Myers Squibb Company, a Delaware corporation with a place of business at Route 206 & Province Line Road, Princeton, NJ 08543 (“BMS”), Medarex, Inc., a New Jersey corporation and a wholly-owned subsidiary of BMS with a principal place of business at 521 Cottonwood Drive, Milpitas, CA 95035 (“Medarex, Inc.”), GenPharm International, Inc., a California corporation and a wholly-owned subsidiary of Medarex with a principal place of business at 521 Cottonwood Drive, Milpitas, CA 95035 (“GenPharm”) (all together “Medarex”), and Genmab A/S, a corporation organized and existing under the laws of Denmark, with a principal place of business at Bredgade 34, DK-1260 Copenhagen K, Denmark (“Genmab”).
AMENDMENT NO. 4 TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN GENMAB A/S AND GLAXO GROUP LIMITED DATED 19 DECEMBER 2006, AS AMENDED (the “Agreement”)The Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
This amendment to the Agreement (“Amendment No. 4”) is made and entered into as of the 20th day of December, 2010 (the “Amendment Effective Date”), between
LICENSE AND COLLABORATION AGREEMENT by and between Seattle Genetics, Inc. and Genmab A/S Effective as of: October 7, 2011License and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations • New York
SEATTLE GENETICS, INC., a Delaware corporation, having its principal place of business at 21823 30th Drive S.E., Bothell, Washington 98021 (hereinafter referred to as “SGI”)
ContractDevelopment and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
AMENDMENT NUMBER 1 TO THE COLLABORATION AND LICENSE AGREEMENT The Collaboration and License Agreement • February 22nd, 2023 • Genmab a/S • Pharmaceutical preparations
This AMENDMENT NUMBER 1 TO THE COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) made as of 8 November, 2022 (the “Amendment No. 1 Effective Date”) by and between Genmab A/S, CVR No. 2102 3884, a Danish corporation having its principal office at Kalvebod Brygge 43, 1560 Copenhagen V, Denmark (“Genmab”) and AbbVie Biotechnology Ltd., a corporation organized under the laws of Bermuda, having a place of business at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda (“AbbVie”), amends the Collaboration and License Agreement between Genmab and AbbVie dated as of June 10, 2020. Genmab and AbbVie are each referred to herein individually as “Party” and collectively “Parties”.
CONTENTSAgreement • March 29th, 2021 • Genmab a/S • Pharmaceutical preparations
[*] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and is the type of information that we treat as private or confidential.
